D
한올바이오파마
009420KOSPI39.5 / 100
Reference Date: 2026-10-23
Financial Score14.0 / 40
News Sentiment12.5 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 16.1% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Hanall BioPharma, established in 1973, focuses on R&D, manufacturing, and sales of synthetic and biopharmaceuticals, with a particular emphasis on developing new drugs for autoimmune diseases, eye conditions, cancer, and neurological disorders. In 2024, the company reported revenue of 138.9 billion KRW, with its subsidiary HPI handling overseas clinical trials and licensing activities.
Number of Employees
315people
Average Salary
82.0M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
12.92Industry Average 1.200.0Point
10.8x industry avg (risky)
ROE
-3.37Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
11.80Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20252.0 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲7.3% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼293.5% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -0.8% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (19%, downtrend)
Current 40,000Won52-week high 70,70052-week low 32,750
1-month return0.0Point
1m -16.05% (strong drop)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-06